2014-11-14T16:00:27-06:00 2013-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2013-01-01 943384500 PATH DRUG SOLUTIONS INST 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA POLIUS CFO 2062853500 2014-11-14 1 3019519090 2013 2015-11-30 17:44:51Z OLIVIA POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 24747241 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. 7 3 0 0 0 0 2365799 24735210 0 0 72342 -11280 14983 95 2453124 24724025 5066914 5369107 0 0 1852778 0 0 0 12937 4732178 3589631 11651870 8958738 -9198746 15765287 28999523 42859417 2883967 977931 26115556 41881486 X PATH DRUG SOLUTIONS (PDS) WORKS TO DEVELOP SAFE AND EFFECTIVE NEW MEDICINES FOR DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN DEVELOPING COUNTRIES AND ENSURE THAT THEY ARE AVAILABLE AND ACCESSIBLE WHERE THEY ARE NEEDED MOST. 0 0 8644420 5369107 ALTHOUGH MANY POOR COUNTRIES NEED NEW, MORE EFFECTIVE, AND LOWER-COST MEDICINES TO MEET CRITICAL HEALTH CHALLENGES (INCLUDING DIARRHEA, MALARIA, AND HIV), RESEARCH AND DEVELOPMENT FOR THESE DRUGS MAY NOT BE A PRIORITY FOR COMMERCIAL PHARMACEUTICAL GROUPS. PDS OVERCOMES THIS BARRIER BY CREATING CROSS-SECTOR COLLABORATIONS, OPENING DOORS FOR THE SHARING AND DONATION OF INTELLECTUAL PROPERTY, AND HARNESSING THE SCIENTIFIC AND MANUFACTURING CAPACITY OF BOTH DEVELOPED AND DEVELOPING COUNTRIES. WE ASSEMBLE EXPERIENCED AND DEDICATED TEAMS; IDENTIFY PROMISING DRUG CANDIDATES; TRANSLATE THESE CANDIDATES INTO SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES; AND COLLABORATE WITH COMPANIES TO MANUFACTURE AND DISTRIBUTE NEWLY APPROVED THERAPIES TO THOSE WHO NEED THEM MOST.IN 2013, THE TEAM ADVANCED MEDICINES AND RESEARCH TO COMBAT TOP THREATS TO WOMEN AND CHILDREN WORLDWIDE. OUR CROSS-SECTOR PARTNERSHIPS CONTINUED TO MODEL BEST PRACTICES IN INNOVATIVE COLLABORATION TO ACHIEVE SHARED PUBLIC HEALTH GOALS. THIS YEAR, THE COMMERCIAL LAUNCH OF A SEMISYNTHETIC VERSION OF ARTEMISININ, THE KEY INGREDIENT IN GOLD-STANDARD ANTIMALARIAL TREATMENTS, MARKED THE CULMINATION OF EFFORTS BEGUN A DECADE AGO.FOR YEARS, THE VOLATILE COST AND FLUCTUATING SUPPLY OF PLANT-DERIVED ARTEMISININ CHALLENGED THE GLOBAL MARKET WITH UNPREDICTABLE AVAILABILITY AND PRICING. PDS WORKED WITH PARTNERS TO DEVELOP A STABLE, AFFORDABLE, SEMISYNTHETIC SOURCE TO SUPPLEMENT THE BOTANICAL SUPPLY. OUR UNIQUE APPROACH BRIDGED THE GAP BETWEEN SMART CONCEPT AND REAL-WORLD IMPACT, BRINGING THE PRODUCT FROM SMALL LABORATORY BATCHES, THROUGH INDUSTRIAL MANUFACTURE, AND ON TO INTRODUCTION. THIS YEAR, OUR FRENCH MANUFACTURING PARTNER, SANOFI, LAUNCHED COMMERCIAL PRODUCTION OF SEMISYNTHETIC ARTEMISININ (SSART), MAKING IT AVAILABLE TO PREQUALIFIED MANUFACTURERS.ALSO THIS YEAR, THE WORLD HEALTH ORGANIZATION ANNOUNCED THAT SSART IS ACCEPTABLE FOR USE IN THE MANUFACTURE OF ARTEMISININ-BASED MEDICINES, MAKING IT EASIER FOR PREQUALIFIED MANUFACTURERS TO BEGIN USING THE INGREDIENT IN THEIR PRODUCTS. A CONSISTENT SUPPLY OF SSART CAN AID IN STABILIZING THE GLOBAL MARKET FOR ARTEMISININ AND, ULTIMATELY, HELP ENSURE THAT LIFESAVING ANTIMALARIAL DRUGS ARE RELIABLY AVAILABLE TO MILLIONS OF PEOPLE. OUR SUCCESS DEMONSTRATES THE POWER OF BROAD COLLABORATION BETWEEN INDUSTRY, SCIENTIFIC, NONPROFIT, AND ACADEMIC PARTNERS TO ACHIEVE SHARED HUMANITARIAN GOALS. IN 2013, PDS ALSO CONTINUED RESEARCH TRIALS TO ADVANCE EFFECTIVE AND AFFORDABLE DRUGS TO TREAT DIARRHEAL DISEASE, ONE OF THE LEADING CAUSES OF DEATH AMONG CHILDREN UNDER FIVE. ALTHOUGH DIARRHEA CAN BE TREATED, EXISTING TOOLS DO NOT ALWAYS REACH PEOPLE WHO NEED THEM. SOMETIMES THIS IS BECAUSE EFFECTIVE TREATMENTS, ALTHOUGH LIFESAVING, DO NOT EASE SYMPTOMS, WHICH CAN DISCOURAGE USE AND ADHERENCE. TO HELP OVERCOME THIS BARRIER, WE ARE DEVELOPING A NEW ANTISECRETORY DRUG CANDIDATE (IOWH032) THAT HAS THE POTENTIAL TO SHORTEN THE DURATION AND SEVERITY OF DIARRHEA SYMPTOMS. FOLLOWING PHASE 1 RESEARCH DEMONSTRATING THAT THE CANDIDATE IS SAFE, WELL-TOLERATED, AND CAUSES NO SERIOUS ADVERSE EVENTS, WE COMPLETED ANOTHER TWO-PART STUDY THIS YEAR AMONG HEALTHY ADULT MALE AND FEMALE VOLUNTEERS, AND ADULT MALES WITH CHOLERA, IN BANGLADESH. BY PROVIDING FASTER RELIEF OF DIARRHEA SYMPTOMS, ANTISECRETORY DRUGS LIKE IOWH032 MAY COMPLEMENT AND ENCOURAGE WIDER ADOPTION OF ORAL REHYDRATION SOLUTION (ORS) AND OTHER PROVEN TREATMENTS. IN ADDITION, WE LAUNCHED A PHASE 2 RANKING TRIAL IN BANGLADESH TO COMPARE AND EVALUATE THREE NEW FORMULATIONS OF ORS, A PROVEN TREATMENT FOR DIARRHEAL DISEASE THAT STILL DOES NOT REACH ENOUGH PEOPLE. IT IS ANTICIPATED THAT THE NEW FORMULATION WILL PROVIDE THE SAME EFFECTIVENESS IN TREATING OR PREVENTING DEHYDRATION AS CONVENTIONAL ORS BUT WITH THE ADDED BENEFIT OF REDUCING THE DURATION OF ILLNESS. WE WILL USE THE TRIAL TO SELECT THE FORMULATION TO ADVANCE TO FURTHER CLINICAL STUDIES.FINALLY, PDS IS DEVELOPING NEW TOOLS TO COMBAT HIV AND AIDS, WHICH CONTINUE TO TAKE THE LIVES OF AN ESTIMATED 2 MILLION PEOPLE EACH YEAR, PRIMARILY IN SUB-SAHARAN AFRICA. WE ARE WORKING WITH PARTNERS TO DEVELOP A LONG-ACTING INJECTABLE DRUG THAT COULD BE USED PREVENTIVELY TO REDUCE THE RISK OF INFECTION IN HEALTHY ADULTS. THIS YEAR, PDS AND A PHARMACEUTICAL PARTNER SIGNED A LICENSING AGREEMENT PAVING THE WAY FOR PHASE 2 MULTISITE SAFETY STUDIES OF THE DRUG IN THE UNITED STATES AND AFRICA IN 2014. THIS EFFORT IS ONE PART OF PATH'S WIDE PORTFOLIO OF HIV PREVENTION STRATEGIES. IN COMBINATION WITH OTHER APPROACHES, IT COULD PROVIDE A POWERFUL TOOL TO STOP THE SPREAD OF HIV. 8644420 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 12 0 1 0 0 1 IN 0 0 0 0 0 0 0 0 X 7 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEVEN B DAVIS PRESIDENT & CEO 1.00 39.00 X X 0 481239 41628 OLIVIA POLIUS TREASURER & CFO (BEGAN 8/23/13) 1.00 39.00 X X 0 99511 6116 ERIC G WALKER TREASURER & CFO (UNTIL 8/23/13) 1.00 39.00 X X 0 352054 34611 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 225160 35498 JACQUELINE SHERRIS DIRECTOR (UNTIL 10/28/13) 2.00 38.00 X 0 208881 27440 TOM BREWER DIRECTOR (UNTIL 11/18/13) 2.00 1.00 X 0 0 0 KEITH CHIRGWIN DIRECTOR (BEGAN 11/18/13) 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 JORGE FLORES DIRECTOR 2.00 0.00 X 0 0 0 DAVID KASLOW DIRECTOR (BEGAN 10/2/13) 2.00 38.00 X 0 322463 39519 0 1689308 184812 0 0 1 0 0 535489 24199721 24735210 11936 11936 23216 -23216 -23216 -23216 OTHER REIMBURSEMENTS 900099 95 95 95 24724025 0 0 -11185 4860772 4860772 508335 508335 104950 100660 4290 1609 1609 329219 326096 3123 1739 1739 93343 49980 42831 532 11595 3362 8128 105 727728 727728 204365 255 204110 505225 503965 1260 109782 109559 223 17010 17010 5110 3434 1676 SUBCONTRACTS 1174694 1174694 EQUIPMENT R&M / PROC. 157755 148757 8998 LAB SUPPLIES 89398 89398 CURRENCY FLUCTUATION 30098 30098 26011 3979 9732 12300 8958738 8644420 301381 12937 277683 763123 21622683 28480673 6799174 13545716 62254 701 138279 35758 87844 56684 97806 31160 1644 2286 28999523 42859417 2883967 977931 2883967 977931 X 620484 1065513 25495072 40815973 26115556 41881486 28999523 42859417 15765287 643 0 X 0 1 X 1 0 X X X 0 0 0 PATH 911157127 7 1 8958738 1 8958738 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8585 3844 4741 79259 52840 26419 31160 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 30840 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 903085 EUROPE 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 41384 EUROPE 0 0 GRANTMAKING 6670 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 1492 NORTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 21015 SOUTH ASIA 0 0 MANAGEMENT & GENERAL 27361 SOUTH ASIA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 268433 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 616017 SOUTH ASIA 0 0 GRANTMAKING 501665 0 0 0 0 0 0 1300280 1117682 2417962 EUROPE PRODUCT DEVELOPMENT 6670 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 252123 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 33790 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 35897 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 17221 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 16914 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 13572 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 12752 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 10144 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 8048 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 91749 CHECK/WIRE 9 1 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ST LOUIS UNIVERSITY 1100 SOUTH GRAND BLVD DOISY RESEARCH CENTER RM 317 ST LOUIS MO 63104 430654872 501(C)(3) 838371 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 4022391 GENERAL SUPPORT 2 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEVEN B DAVIS PRESIDENT & CEO 0 420801 0 59938 0 500 0 30600 0 11028 0 522867 0 0 ERIC G WALKER TREASURER & CFO (UNTIL 8/23/13) 0 351054 0 0 0 1000 0 25448 0 9163 0 386665 0 0 DANIEL LASTER SECRETARY 0 224390 0 0 0 770 0 24497 0 11001 0 260658 0 0 JACQUELINE SHERRIS DIRECTOR (UNTIL 10/28/13) 0 208637 0 0 0 244 0 24564 0 2876 0 236321 0 0 DAVID KASLOW DIRECTOR (BEGAN 10/2/13) 0 322388 0 0 0 75 0 28491 0 11028 0 361982 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING METHODS TO ESTABLISH COMPENSATION: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE FINAL 990 WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CFO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PDS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PDS DOES NOT HAVE EMPLOYEES. PDS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF IRC SECTION 509(A)(3), AND PDS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF ABOVE A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PDS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 ORGANIZATION FOR APPROPRIATE TECHNOLOGY IN HEALTH 25 BUILDING B0 SHOTA RUSTAVELI STR KYIV UP REDUCE THE TB BURDEN IN UKRAINE UP N/A N/A PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0